Takeda Pharmaceutical Net Income Growth & History (TAK)

Takeda Pharmaceutical's net income was −¥152.39B for fiscal 2026.

View full Takeda Pharmaceutical company overview

Takeda Pharmaceutical annual net income history

Takeda Pharmaceutical annual net income

Fiscal yearPeriod endedNet incomeChangeGrowth
20262026-03-31−¥152.39B−¥260.53B
20252025-03-31¥108.14B−¥36.05B−25.00%
20242024-03-31¥144.20B−¥172.84B−54.52%
20232023-03-31¥317.04B¥86.87B+37.74%
20222022-03-31¥230.17B−¥146.00B−38.81%
20212021-03-31¥376.17B¥331.88B+749.34%
20202020-03-31¥44.29B−¥90.79B−67.21%
20192019-03-31¥135.08B−¥51.63B−27.65%
20182018-03-31¥186.71B¥71.19B+61.63%
20172017-03-31¥115.51B

Takeda Pharmaceutical net income trends

Over the last five fiscal years, Takeda Pharmaceutical's net income decreased from ¥376.17B to −¥152.39B, a change of −¥528.56B. The latest reported quarter, Q1 2027, shows ¥113.20B.

About the metric

What net income means

Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.

Calculation and source

SEC-reported net income

TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Takeda Pharmaceutical source filings ↗

Community posts

It’s quiet here.

No posts about TAK yet. Start the conversation.

Write the first post